Fenofibrate tablets are a commonly used fibrate lipid-regulating drug for lowering triglycerides with a clear efficacy, but safety issues requiring key attention exist during medication, including hepatotoxicity, myopathy risk, and drug interactions. Standardized monitoring, rational combination use, and timely identification of danger signals are the core of safe medication.
Pre-medication screening: Liver function should be checked before starting treatment; it is contraindicated in patients with active liver disease or severe hepatic insufficiency.
Regular monitoring: Transaminases should be rechecked regularly in the early stage of medication and during dose adjustment, and follow-up should be conducted according to medical advice thereafter.
Graded management: Mild elevation of transaminases may be continuously observed under the guidance of a doctor; if the elevation exceeds 3 times the upper limit of normal, or jaundice, weakness, loss of appetite, or darkening of urine occurs, the drug should be stopped and medical attention sought promptly.
Avoid taking it with alcohol to reduce the burden on the liver.
Typical signals: Unexplained muscle pain, tenderness, weakness, or tea-colored urine should prompt immediate drug discontinuation and medical attention to test creatine kinase (CK).
High-risk combination use: Combination with statin lipid-regulating drugs significantly increases the risk of myopathy and rhabdomyolysis, and the necessity must be evaluated by a doctor with close CK monitoring; the risk is also increased when combined with drugs such as cyclosporine.
Other triggers: Renal insufficiency, hypothyroidism, strenuous exercise, and heavy alcohol consumption can increase the risk of myopathy, and these should be reported to the doctor and avoided.
Statins: Combination use increases the risk of myopathy and requires caution and monitoring.
Anticoagulants such as warfarin: Fenofibrate can enhance the anticoagulant effect; coagulation indicators (INR) should be monitored during combination use, and the anticoagulant dose adjusted if necessary.
Cyclosporine: It can increase the blood concentration of fenofibrate and increase the risk of nephrotoxicity and myopathy; combination use is generally avoided.
Sulfonylurea hypoglycemic drugs: The hypoglycemic effect may be enhanced; monitor blood glucose and be alert to hypoglycemia.
Proactively inform the doctor of all medications being taken, including health supplements and Chinese herbal medicines, when visiting a doctor.
Disclaimer:《Precautions for taking fenofibrate tablets: hepatotoxicity, myopathy risk, and drug interactions》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication!
Full Name:Fenofibrate、Lipidil、非诺贝特片
Reference Price:$230.00
Prescribing Information: 非诺贝特片为一种调血脂药物,主要适用于高脂血症的治疗。其通过激活过氧化物酶体增殖物激活受体α(PPARα),调节与脂质代谢相关的基因表达,从而有效降低血清总胆固醇和甘油三酯水平,并提升高密度脂蛋白胆固醇水平。 一、药品名称 非诺贝特片(Lipidil),商品名:リピディル錠,有...